Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors

Dimopoulou, Dimitra; Vartzelis, George; Dasoula, Foteini; Τσολιά, Μαρία; Maritsi, Despoina

doi:10.1136/annrheumdis-2021-221607

Cited by 15 publications

(20 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, there is a theoretical risk for RMDs flare post COVID-19 vaccination; however, the estimated risks and benefits clearly favour vaccination and it is currently recommended COVID-19 vaccination for patients with rheumatic diseases [ 19 ]. No disease flare was observed at 1 month and 3 months follow-up post immunization in our cohort [ 8 ]. This is in accordance with other reports, showing that immunization does not provoke flares of underlying RMDs [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…Follow-up visits were planned at 1, 3 and 6 months. Blood samples for the evaluation of vaccine immunogenicity were collected from all of subjects at the time of enrolment, as well as at 1, 3 and 6 months after the second vaccine dose [ 7 , 8 ]. Blood samples were collected in specific containers, were centrifuged and quantitative measurement of IgG antibodies to SARS-CoV-2 spike protein-1 was performed in serums of the patients with a cut-off level of 100 rU/ml (Euroimmun Quantivac-Elisa-IgG assay).…”

Section: Methodsmentioning

confidence: 99%

“…To date, data regarding the long-term immunogenicity of COVID-19 vaccination in adolescents with RMDs on immunosuppressants are scarce, as these individuals were excluded from the vaccine trials [ 6 ]. In our previous studies, we presented the results about safety and immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNFi at 3 months following immunization [ 7 , 8 ]. The purpose of the present study was to evaluate the immunogenicity 6 months after BNT162b2-COVID-19 vaccination in this specific population.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objectives Mass vaccination is the most effective strategy for controlling the COVID-19 pandemic. This study aimed to evaluate the 6-month immunogenicity after BNT162b2-COVID-19 vaccination in adolescents with JIA on TNFi treatment. Methods This single-center study included adolescents with JIA treated with TNFi for at least 18 months. Patients received two doses of COVID-19 vaccine (Pfizer-BioNTech) from April 15th to May 15th 2021. Quantitative measurement of IgG antibodies to SARS-CoV-2-spike-protein-1 was performed at 1,3 and 6 months post-vaccination. Results Overall, 21 adolescents with JIA in clinical remission at the time of vaccinations were enrolled. None of them discontinued TNFi/MTX treatment at the time of vaccine administration or during the follow-up period. All patients developed a sustained humoral response against SARS-CoV-2 at 1 and 3 months after vaccination (p< 0.05). The antibody levels decreased significantly at 6 months post-vaccination (p< 0.01). The type of JIA did not reveal any differences in the humoral response at 3 (p= 0.894) or 6 months post-vaccination (p= 0.72). No difference was detected upon comparison of the immunogenicity between the different treatment arms (adalimumab vs etanercept) at 3 (p= 0.387) and 6 months (p= 0.526), or TNFi monotherapy vs combined therapy (TNFi plus methotrexate) at 3 (p= 0.623) and 6 months (p= 0.885). Conclusions Although mRNA vaccines develop satisfactory immunogenicity at 1- and 3-months post-vaccination in adolescents with JIA on TNFi, SARS-CoV-2 antibody titers decrease significantly overtime, remaining at lower levels at 6 months. Further collaborative studies are required to determine long-term immunogenicity, real duration of immune protection and the need for a booster vaccine dose.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In accordance with the current results, Dimopoulou et al studied safety of the BNT162b2 COVID-19 vaccine in adolescents with JIA on biological therapy and revealed post-vaccination local AE in 74%. However, systemic adverse events were revealed in only 19%, but this study did not include several systemic adverse events like fever, chills, nausea, chest pain and diarrhea [ 11 ]. In another study that looked at the safety of another mRNA COVID-19 vaccine on adolescents aged 12–17 years old, systemic adverse events were reported in 68.5% and 86% of the cases after the first and second doses, respectively, and they were generally mild to moderate [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Safety of the BNT162b2 mRNA COVID-19 vaccine in children and adolescents with juvenile idiopathic arthritis: a tertiary-center early experience

Abdelgalil

Bakry

Muzaffer

2022

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

Background Research on the COVID-19 vaccination in patients with underlying rheumatic disorders in pediatric age is lacking. We studied possible adverse events of the mRNA BNT162b2 vaccine against SARS-CoV-2 (Pfizer-BioNTech) in children and adolescents with juvenile idiopathic arthritis (JIA), and also if there is a risk of flaring of the underlying JIA. We reported 36 JIA patients aged 5–18 years old received 2 doses of the COVID-19 vaccine (72 doses). Patients were followed before and after vaccination, and any related adverse event was recorded. JIA disease activity was assessed using Juvenile Arthritis Disease Activity Score-10 (JADAS-10) before and after vaccination. Results Among 72 doses of the vaccine received, local adverse events (AEs) were reported by majority of the patients (66.7%); most commonly reported local AE was pain at the site of injection. Systemic AEs were revealed by (65.3%), most commonly reported systemic AEs were tiredness, myalgia, and headache. Almost all the reported AE were mild to moderate and resolved within 1–2 days and were also more frequently noted after the second dose. No flaring of the underlying primary rheumatic disease after vaccination. No one of the study group revealed serious adverse events. Conclusions This is one of the early studies reporting that mRNA COVID-19 vaccine seems to be safe in children and adolescents with JIA. Almost all the reported adverse events were mild to moderate and transient. Also, no serious adverse events or flaring of the primary disease were reported.

show abstract

“…The research showed that mRNA vaccines develop satisfactory immunogenicity at 1 and 3 months post immunisation. The vaccine assures an adequate humoral response against SARS-CoV-2 [ 135 ].…”

Section: Study Of Covid-19 In Particularly Vulnerable Childrenmentioning

confidence: 99%

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment

et al. 2021

View full text Add to dashboard Cite

Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors

Cited by 15 publications

References 9 publications

Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors

Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors

Safety of the BNT162b2 mRNA COVID-19 vaccine in children and adolescents with juvenile idiopathic arthritis: a tertiary-center early experience

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment

Contact Info

Product

Resources

About